In addition to approved drugs duloxetine, pregabalin, and tapentadol, some benefits were found with venlafaxine, oxcarbazepine, tricyclic antidepressants, tramadol, and botulinum toxin.
In adults with uncontrolled type 2 diabetes who initially declined insulin versus those who initially accepted, median time to an HbA1c level below 7.0% was 50 months versus 38 months.
Real-time continuous glucose monitoring (CGM), with either an insulin pump or multiple daily injections, was associated with sustained improvements in HbA1c levels compared to self-monitoring of blood glucose, according to a small randomized trial.
The results highlight the heterogeneity of type 2 diabetes and may help explain the differences in disease progression and response to glucose-lowering treatment seen in clinical practice, an accompanying comment
probably indicates a more accelerated intimal hyperplasia, greater degree of vascular inflammation and/or endothelial dysfunction, and increased plaque vulnerability in insulin-treated diabetic patients, and highlights the need for
An analysis of patients with insulin-treated diabetes found that 38% of those with late-onset type 1 diabetes did not receive insulin at diagnosis, nearly half of whom reported a type 2 diabetes diagnosis.
A recent scientific statement on diabetes and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes on outcomes in heart failure; reviews pharmacological therapy and lifestyle modification; highlights the value
Other independent predictors of long-term weight loss included greater weight loss in the first year and older age, according to this follow-up analysis of the Diabetes Prevention Program.
Patients with type 1 diabetes and a mean three-year HbA1c level greater than 8.0% had a higher fracture risk than those with a mean three-year HbA1c level of 7.0% or less.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with fewer hospitalizations for heart failure and slower progression of kidney disease while glucagon-like peptide-1 (GLP-1) receptor agonists were associated with lower risk of stroke